Injectable HIV therapy outperforms daily pills in adolescents trial

The LATA trial, a randomised, open-label, multicentre non-inferiority study across five clinics in Kenya, South Africa, Uganda, and Zimbabwe, compared long-acting injectable cabotegravir-rilpivirine given every 8 weeks with daily oral ART in virologically suppressed adolescents living with HIV. The trial reported that by week 96, 0.9% of participants on the injectable regimen had confirmed viral load of 50 copies per mL or higher versus 6.4% on oral ART, meeting non-inferiority and demonstrating statistical superiority. The authors state that adverse event profiles were similar between groups aside from injection-site reactions, with no new safety concerns observed, and conclude these findings support the injectable regimen as a maintenance treatment option for this population.

Most relevant for: Adolescents aged 12 to under 20 years living with HIV who have achieved virological suppression on antiretroviral therapy in sub-Saharan African care settings.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.